GeneDx Holdings Corp vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? GeneDx Holdings Corp trades at $81.63 (market cap $2.44B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.31. The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| WGS | YMAG | |
|---|---|---|
Market Cap | $2.44B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $167.51 | $15.98 |
52-Week Low | $34.51 | $10.76 |
Enterprise Value | $2.48B | — |
Signals from Pluang's Aura AI — not financial advice
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
YMAG trades at $11.33, down 2.24% today, with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, with recent payments ranging from $0.07 to $0.40 per share. Technical indicators show strong trend momentum with ADX readings above 25, while RSI suggests potential overbought conditions on shorter timeframes.
YMAG's option income strategy generates substantial distributions but faces NAV stability challenges during earnings periods. The fund's structure effectively monetizes volatility in rangebound markets, though concentrated exposure to Magnificent Seven stocks creates single-sector risk. Current price action tests key support at $11-$12 resistance levels.
Trailing returns across standard periods
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →